Text Size

Activity Monitoring Assessment of Opiate Withdrawal - 4

This study has been completed.
Sponsor:
Collaborator:
Washington DC VA
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000335
First received: September 20, 1999
Last updated: March 20, 2013
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to determine if hyperactivity accompanies abrupt opiate withdrawal in heroin addicts, to determine if computerized solid state activity monitors are capable of quantifying hyperactivity, and to quantify the physical and affective symptoms occurring during abrupt withdrawal in heroin addicts and morphine's capacity to alleviate these symptoms.


Condition Intervention Phase
Opioid-Related Disorders
 Drug: Morphine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Activity Monitoring Assessment of Opiate Withdrawal

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Anxiety
  • Withdrawal severity
  • Activity
  • Opiate secondary withdrawal

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000335

Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington DC VA
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington DC VA
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000335     History of Changes
Other Study ID Numbers: NIDA-3-0009-4, Y01-3-0009-4
Study First Received: September 20, 1999
Last Updated: March 20, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Morphine
Analgesics, Opioid
Analgesics
Sensory System Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on May 23, 2013